Related Experiment Videos
[Chemoradiation therapy for esophageal carcinoma]
T Konishi1, S Shimoyama, A Ito
1Department of Surgery, Showa General Hospital, Tokyo, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|December 6, 1997
Summary
Preoperative chemoradiation therapy improves outcomes for esophageal cancer patients. This treatment, combining chemotherapy and radiation before surgery, increases resection rates and survival for locally advanced tumors.
Area of Science:
- Oncology
- Surgical Oncology
- Radiation Oncology
Context:
- Esophageal cancer presents significant challenges in surgical, medical, and radiation treatment.
- Despite advancements, surgical resection prognosis for esophageal cancer remains suboptimal.
- Locally advanced tumors require improved therapeutic strategies.
Purpose:
- To evaluate the efficacy of preoperative chemoradiation therapy for esophageal cancer.
- To assess the impact of concurrent 5-fluorouracil, cis-platinum, and radiation on patient outcomes.
- To determine if this neoadjuvant approach improves resection rates, pathological response, and survival.
Summary:
- Preoperative chemoradiation therapy, combining 5-fluorouracil, cis-platinum, and radiation, is increasingly studied for squamous cell esophageal carcinoma.
- This neoadjuvant treatment demonstrates potential to increase resection rates and pathological complete response (up to 42.1%) in locally advanced esophageal cancer.
- Reported major antitumor responses range from 40% to 80% in clinical trials.
Impact:
- Preoperative chemoradiation therapy offers a promising strategy for improving the prognosis of patients with locally advanced esophageal cancer.
- This approach may enhance surgical resectability and patient survival following esophagectomy.
- The findings support the consideration of neoadjuvant chemoradiation as a standard treatment modality.